Oral direct renin inhibitor aliskiren reduces in vivo oxidative stress and serum matrix metalloproteinase-2 levels in patients with permanent atrial fibrillation

MLA

Yoshizumi Takei, Md, et al. “Oral Direct Renin Inhibitor Aliskiren Reduces in Vivo Oxidative Stress and Serum Matrix Metalloproteinase-2 Levels in Patients with Permanent Atrial Fibrillation.” Journal of Arrhythmia, vol. 31, no. 2, Apr. 2015, pp. 76–77. EBSCOhost, https://doi.org/10.1016/j.joa.2014.07.002.

APA

Yoshizumi Takei, M., Minoru Ichikawa, M., PhD, & Yoshiyuki Kijima, M., PhD. (2015). Oral direct renin inhibitor aliskiren reduces in vivo oxidative stress and serum matrix metalloproteinase-2 levels in patients with permanent atrial fibrillation. Journal of Arrhythmia, 31(2), 76–77. https://doi.org/10.1016/j.joa.2014.07.002

Chicago

Yoshizumi Takei, Md, Md Minoru Ichikawa PhD, and Md Yoshiyuki Kijima PhD. 2015. “Oral Direct Renin Inhibitor Aliskiren Reduces in Vivo Oxidative Stress and Serum Matrix Metalloproteinase-2 Levels in Patients with Permanent Atrial Fibrillation.” Journal of Arrhythmia 31 (2): 76–77. doi:10.1016/j.joa.2014.07.002.